Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$144 Mln
P/E Ratio
--
P/B Ratio
2.38
Industry P/E
--
Debt to Equity
0.08
ROE
-0.61 %
ROCE
-53.15 %
Div. Yield
0 %
Book Value
2.42
EPS
-1.11
CFO
$-150.63 Mln
EBITDA
$-165.13 Mln
Net Profit
$-187.91 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Profound Medical (PROF)
| -38.08 | -31.72 | -36.48 | -40.00 | -16.58 | -16.79 | -- |
|
BSE Sensex
| 1.72 | 3.50 | 4.95 | 8.90 | 11.18 | 21.04 | 11.14 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Profound Medical (PROF)
| -22.04 | -3.03 | -45.38 | 87.76 | 160.71 | -35.49 | -17.98 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 12.60 | 4,260.47 | -- | -4.76 | |
| 2.04 | 85.75 | -- | -6.72 | |
| 2.33 | 1,388.99 | -- | 2643.32 | |
| 6.76 | 262.03 | 23.68 | 9.19 |
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United... States, and Finland. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada. Address: 2400 Skymark Avenue, Mississauga, ON, Canada, L4W 5K5 Read more
Chairman of the Board & CEO
Dr. Arun Swarup Menawat MBA, Ph.D.
Chairman of the Board & CEO
Dr. Arun Swarup Menawat MBA, Ph.D.
Headquarters
Mississauga, ON
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Profound Medical Corp (PROF) stood at $ 70 Mln as on 31-Dec-24
The share price of Profound Medical Corp (PROF) is $4.65 (NASDAQ) as of 22-Apr-2025 12:12 EDT. Profound Medical Corp (PROF) has given a return of -16.58% in the last 3 years.
Profound Medical Corp (PROF) has a market capitalisation of $ 144 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Profound Medical Corp (PROF) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Profound Medical Corp (PROF) and enter the required number of quantities and click on buy to purchase the shares of Profound Medical Corp (PROF).
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada. Address: 2400 Skymark Avenue, Mississauga, ON, Canada, L4W 5K5
The CEO & director of Dr. Arun Swarup Menawat MBA, Ph.D.. is Profound Medical Corp (PROF), and CFO & Sr. VP is Dr. Arun Swarup Menawat MBA, Ph.D..
There is no promoter pledging in Profound Medical Corp (PROF).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
640
|
|
|
35
|
|
|
26
|
|
|
12
|
| Profound Medical Corp. (PROF) | Ratios |
|---|---|
|
Return on equity(%)
|
-60.73
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-260.45
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Profound Medical Corp (PROF) was $0 Mln.
$0.09
(
